Previous 10 | Next 10 |
home / stock / fphaf / fphaf news
Bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumors CLEVER-1 targeting is safe and well-tolerated with no serious adverse effects Bexmarilimab induced macrophage activation and increased IFNɣ sign...
(NewsDirect) Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warner from Proactive London after the clinical-stage biopharmaceutical company announced it has initiated Phase 2 of its BEXMAB Study of Bexmarilimab in HMA-failed myelody...
TURKU, Finland and BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will present Phase 1/2 data from its ongoing BEXMAB st...
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, SINGAPORE, HONG KONG OR ANY OTHER JURI...
(NewsDirect) Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief executive Dr Markku Jalkanen speaks to Thomas Warner from Proactive London after the clinical stage biopharmaceutical company revealed fresh data from the company's ongoing phase I/II trial. Its BEXMAB study is eva...
Bexmarilimab produces a 50% remission rate in doublet dose cohorts (11 out of 22 patients) Eight of the 11 patients are Complete Responders (CR) or CR with incomplete blood recovery (CRi) Highest overall response rate (ORR) of 80% observed in prior HMA-failure MDS group (4 out of 5 pati...
TURKU, Finland and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage re-programming for effective cancer immunotherapies, today announces it will host a virtual call for investors to...
TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, is pleased to announce the appointment of Ms. Christine Roth and Dr. Marie-Lo...
TURKU, Finland and BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces that the extraordinary general meeting (the "EGM") of the Company to...
• Dr. Marie-Louise Fjällskog, outgoing CMO, is proposed to continue key role in bexmarilimab’s development as a Board member Company announcement, September 21, 2023 TURKU, Finland and BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: F...
News, Short Squeeze, Breakout and More Instantly...
Faron Pharmaceuticals Oy Company Name:
FPHAF Stock Symbol:
OTCMKTS Market:
Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients. 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up. While data do not yet all...
(NewsDirect) Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndr...
TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvi...